Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study by Pedersen Rasmus Steen, Damkier Per, Brosen Kim in Clinical pharmacology and therapeutics (2005).

[PMID: 15961977] PubMed


Polymorphic cytochrome P450 (CYP) 2D6 activity has been shown to be a determinant of the pharmacokinetics and pharmacodynamics of tramadol via hepatic phase I O -demethylation of (+)-tramadol to (+)-O-desmethyltramadol. Our objective was to investigate whether tramadol can be used as a probe for CYP2D6 phenotyping by determining the concordance between the 8-hour tramadol and 12-hour sparteine metabolic urinary ratios.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.